Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics

Core Insights - Amicus Therapeutics reported revenue of $169.06 million for the quarter ended September 2025, marking a year-over-year increase of 19.5% and an EPS of $0.17 compared to $0.10 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $164.76 million by 2.61%, and the EPS surpassed the consensus estimate of $0.12 by 41.67% [1] Financial Performance - Geographic net product sales outside the U.S. were $98.79 million, slightly below the estimated $100.21 million, reflecting a year-over-year increase of 15.8% [4] - U.S. geographic net product sales reached $70.27 million, exceeding the average estimate of $64.47 million, with a year-over-year growth of 25.1% [4] - Net product sales for Pombiliti and Opfolda totaled $30.71 million, surpassing the estimated $29.77 million, representing a significant year-over-year increase of 45.3% [4] - Net product sales for Galafold were reported at $138.35 million, below the average estimate of $150.1 million, but still showing a year-over-year growth of 14.9% [4] Stock Performance - Shares of Amicus Therapeutics have returned +10.2% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]